GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Annual Report 2020-21 217 Note 51 : Related Party Disclosures Related party disclosures, as required by IND AS 24, “Related Party Disclosures”, notified under Section 133 of the Companies Act, 2013 are given below: 1 Relationships (during the year): (i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Company : Glaxo Group Limited, U.K. GlaxoSmithKline Pte Limited, Singapore Eskaylab Limited, U.K. Burroughs Wellcome International Limited, U.K. Holding company / ultimate holding company of the above shareholders GlaxoSmithKline Plc, U.K. * GlaxoSmithKline Finance Plc, U.K.* Setfirst Ltd, U.K. * SmithKline Beecham Limited, U.K. Wellcome Limited, U.K.* The Wellcome Foundation Limited, U.K.* Wellcome Consumer Healthcare Limited, U.K.* * no transactions during the year (ii) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists and with whom the Company had transactions during the year: GlaxoSmithKline Asia Private Limited, India GlaxoSmithKline Brasil Ltda, Brazil* GlaxoSmithKline Consumer Healthcare Limited, India* GlaxoSmithKline Biologicals S.A., Belgium GlaxoSmithKline Pharmaceuticals S.A., Belgium GlaxoSmithKline Services Unlimited, U.K. Glaxo Operations UK Limited, U.K Laboratoire GlaxoSmithKline S.A.S., France* GlaxoSmithKline Pharmaceutical Sdn Bhd, Malaysia GlaxoSmithKline Export Limited, U.K. SmithKline Beecham Pharmaceuticals, U.S.A GlaxoSmithKline Latin America S.A* GlaxoSmithKline Pakistan Limited, Pakistan* GlaxoSmithKline Research & Development Ltd, U.K GlaxoSmithKline Corporate Centre, U.S.A* GlaxoSmithkline Philippines Inc., Philippines* GlaxoSmithKline Australia Pty Limited, Australia* GlaxoSmithKline Canada Inc, Canada*